NEW YORK (GenomeWeb) – OncoDNA said today it has signed an agreement with Cryogene, its distributor in the Middle East, to launch a study using OncoDNA’s liquid biopsy technology to assess the clinical utility of personalized treatments for patients with metastatic cancer.
The study will look at 100 patients across medical centers in Lebanon, Jordan, Saudi Arabia, and the United Arab Emirates, and will use OncoDNA’s OncoSTRAT&GO and OncoTRACE products for profiling circulating tumor DNA in these patients with the aim of exploring whether such profiles can inform treatment options.
The study will look at four cohorts of 25 subjects each: one in advanced refractory ovarian cancer, one in metastatic triple-negative breast cancer, one in cancer of unknown origin, and one in rare cancers.
“This prospective research is the first of its kind in this region,” Fiona Demol, international business development manager at OncoDNA, said in a statement. “Cancer patients will have the opportunity to be screened with a state-of-the-art and unique solution that will identify the most adequate treatment options according to their condition.”
The companies said they plan to complete recruitment for the study by the end of 2017.